UK markets closed
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • FTSE 250

    20,051.48
    -104.32 (-0.52%)
     
  • AIM

    920.38
    -2.34 (-0.25%)
     
  • GBP/EUR

    1.1855
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.2069
    -0.0089 (-0.73%)
     
  • BTC-GBP

    19,266.71
    -2.59 (-0.01%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • DOW

    32,803.47
    +76.67 (+0.23%)
     
  • CRUDE OIL

    88.53
    -0.48 (-0.54%)
     
  • GOLD FUTURES

    1,792.40
    +1.20 (+0.07%)
     
  • NIKKEI 225

    28,175.87
    +243.67 (+0.87%)
     
  • HANG SENG

    20,201.94
    +27.94 (+0.14%)
     
  • DAX

    13,573.93
    -88.77 (-0.65%)
     
  • CAC 40

    6,472.35
    -41.04 (-0.63%)
     

Roche, Merck & Co, and Bayer Among Leading Companies in the Glioblastoma Multiforme Market | GlobalData Plc

  • Oops!
    Something went wrong.
    Please try again later.
·9-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
GlobalData UK Ltd
GlobalData UK Ltd

The US is expected to retain its position as the largest market for glioblastoma multiforme in 2030

LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- The “Glioblastoma Multiforme: Global Drug Forecast and Market Analysis to 2030” report offered by GlobalData provide opportunities for various marketed agents and pipeline agents in development across the 8MM, clinical and commercial assessments for agents in late-stage clinical development, R&D strategies, and innovative approaches in development for glioblastoma multiforme.

The total sales of glioblastoma multiforme (GBM) therapies was estimated to be $549.1 million in 2020 across the 8MM and is expected to increase at a CAGR of more than 4% by 2030. The market growth will be driven by the anticipated launch of eight pipeline agents, of which cancer vaccines and protein kinase inhibitors are the dominating classes.

To get comprehensive statistics on glioblastoma multiforme market sizing and forecast, download a sample report

Glioblastoma Multiforme Market Drivers

  • Approvals and launches of high-priced therapeutics during the forecast period in the 8MM, which include two cancer vaccines, three protein kinase inhibitors, and three small molecule chemotherapies.

  • An increasing number of incident cases of GBM, particularly in the US (due to underlying population growth) and China (due to urbanization).

  • A high level of unmet need in GBM warrants faster uptake of the pipeline agents expected to launch during the forecast window, as patients have few other treatment options.

For more insights on the GBM market drivers and challenges, download a sample report

Glioblastoma Multiforme Market - Unmet Needs and Opportunity Assessment

GBM treatment is an area of high unmet need due to the poor overall survival of GBM patients, the lack of marketed products for this indication, and recent failures in the late-stage pipeline. Identifying biomarkers that are predictive of therapeutic efficacy is an unmet need where GBM has historically had a lack of progress. Biomarker-driven targeted therapy, which shows improved clinical responses, could aid in the approval of several late-stage drug candidates in GBM by using a surrogate endpoint.

For more insights on the unmet needs and opportunities in the GBM market, download a sample report

Glioblastoma Multiforme Market - Pipeline Assessment

After several Phase III trial failures in recent years, the late-stage pipeline is weakened. However, there are eight therapies in Phase II/III or III trials for GBM expected to launch in the 8MM. Driven by the rapid advancement in genetic profiling of GBMs, together with an improved understanding of the GBM immune evasion mechanisms, there has been a potentiated effort in exploring novel treatment approaches within the field of precision medicine.

For more insights on the GBM drugs pipeline and forecast, download a sample report

Glioblastoma Multiforme Market - Competitive Landscape

The current major player in the GBM market with regards to sales is Roche’s Avastin. Roche’s GBM portfolio consists solely of Avastin, which is not approved in Europe. Still, it witnesses off-label use as per market research conducted by GlobalData as a drug of choice in managing edema and reducing steroid burden.

Leading Companies in the Glioblastoma Multiforme Market

  • Roche

  • Merck & Co

  • Bayer

  • Kintara Therapeutics

  • Kazia Therapeutics

To know more about the leading companies in the GBM market, download a sample report

Glioblastoma Multiforme Market Report Scope

  • Overview of glioblastoma multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

  • Topline glioblastoma multiforme market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.

  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting glioblastoma multiforme therapeutics sales in the 8MM.

  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).

  • Analysis of the current and future market competition in the global glioblastoma multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global glioblastoma multiforme therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global glioblastoma multiforme market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track drug sales in the global glioblastoma multiforme therapeutics market from 2020-2030.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Related Reports

  • Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here

  • Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here

  • Endometriosis – Global Drug Forecast and Market Analysis to 2030 – Click here

  • Hemophilia A and B – Global Drug Forecast and Market Analysis, 2021-2030 – Click here

  • Chronic Myeloid Leukemia (CML): Global Drug Forecast and Market Analysis to 2030 – Click here

Glioblastoma Multiforme Market Overview

Market Size 2020

$549.1 million

CAGR

>4%

Forecast Period

2021-2030

Leading Companies

Roche, Merck & Co., Bayer, Kintara Therapeutics, and Kazia Therapeutics

FAQs

What was the glioblastoma multiforme market size in 2020?
The GBM market size was valued at $549.1 million in 2020.

What is the glioblastoma multiforme market growth rate?
The GBM market is projected to grow at a CAGR of more than 4% during the forecast period, 2021-2030.

Which are the leading companies in the glioblastoma multiforme market?
Some of the leading companies in the GBM market are Roche, Merck & Co., Bayer, Kintara Therapeutics, and Kazia Therapeutics.

Table of Contents

1 Glioblastoma Multiforme: Executive Summary

1.1 The Glioblastoma Multiforme Market is Forecast to Reach $868.5M by 2030 Across the 8MM

1.2 GBM-AGILE Candidates Set to Penetrate the Market While Merck & Co. Expands its Early-Stage Portfolio and Roche Experiences Erosion

1.3 High Unmet Needs Exist in the GBM Market, Especially in MGMT-Promoter Unmethylated Patients and Unresectable Patients

1.4 Opportunities for New Entrants with Better Markers of Prognosis and Drug Targets

1.5 Novel GBM-AGILE Drug Candidates and Immunotherapies Expected to Launch During the Forecast Period

1.6 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 8MM Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Diagnosed Incident Cases of Brain Cancer

4.4.4 Diagnosed Incident Cases of Brain Cancer by Type

4.4.5 Diagnosed Incident Cases of Glioblastoma by Grade

4.4.6 Diagnosed Incident Cases of Glioblastoma by Origin

4.4.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

4.4.8 Diagnosed Incident Cases of Glioblastoma by Mutations

4.4.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

4.5 Discussion

4.5.1 Epidemiological Forecast Insight

4.5.2 COVID-19 Impact

4.6 Epidemiological Forecast for Brain Cancer (2020–2030)

4.6.1 Diagnosed Incident Cases of Brain Cancer

4.6.2 Age-Specific Diagnosed Incident Cases of Brain Cancer

4.6.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer

4.6.4 Diagnosed Incident Cases of Brain Cancer by Type

4.6.5 Diagnosed Incident Cases of Glioblastoma by Grade

4.6.6 Diagnosed Incident Cases of Glioblastoma by Origin

4.6.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers

4.6.8 Diagnosed Incident Cases of Glioblastoma by Mutations

4.6.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer

4.6.10 Limitations of the Analysis

4.6.11 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Identification and Validation of Biomarkers and Drug Targets

7.3 Overcoming the Blood-Brain Barrier to Improve the Efficacy of Treatments

7.4 Better Treatment Options for MGMT Unmethylated and Unresectable Patients

7.5 Differentiating Pseudoprogression and True Progression

9 R&D Strategies

9.1 Overview

9.1.1 The Efficacy of Immunotherapy in GBM

9.1.2 Predictive Biomarkers and Targeted Therapy

9.1.3 Improving Therapy Administration Routes

9.2 Clinical Trials Design

9.2.1 Clinical Endpoints

9.2.2 More Umbrella or Platform Trial Designs

9.2.3 Comparator Arms

10 Pipeline Assessment

10.1 Overview

10.2 Promising Drugs in Clinical Development

11 Pipeline Valuation Analysis

11.1 Overview

11.2 Competitive Assessment

12 Current and Future Players

12.1 Overview

12.2 Deal-Making Trends

13 Market Outlook

13.1 Global Markets

13.1.1 Forecast

13.1.2 Drivers and Barriers – Global Issues

13.2 US

13.2.1 Forecast

13.2.2 Key Events

13.2.3 Drivers and Barriers

13.3 5EU

13.3.1 Forecast

13.3.2 Key Events

13.3.3 Drivers and Barriers

13.4 Japan

13.4.1 Forecast

13.4.2 Key Events

13.4.3 Drivers and Barriers

13.5 China

13.5.1 Forecast

13.5.2 Key Events

13.5.3 Drivers and Barriers

14 Appendix

14.1 Bibliography

14.2 Abbreviations

14.3 Methodology

14.3.1 Forecasting Methodology

14.4 Primary Research – KOLs Interviewed for This Report

14.4.1 KOLs

14.5 Primary Research – Prescriber Survey

14.6 About the Authors

14.6.1 Analyst

14.6.2 Therapy Area Director

14.6.3 Epidemiologist

14.6.4 Managing Epidemiologist

14.6.5 Global Director of Therapy Analysis and Epidemiology

14.6.6 Global Head and EVP of Healthcare Operations and Strategy

14.1 Contact Us

About us

GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

GlobalData

Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com

+44 (0)207 936 6400


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting